COVID-19 Stroke Apical Lung Examination Study

COVID-19 Stroke Apical Lung Examination Study - A Multi-centre Prospective Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04640428

Enrollment

2000

Registered

2020-11-23

Start date

2020-07-10

Completion date

2021-10-31

Last updated

2021-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19, Stroke, Acute, Stroke Hemorrhagic, Stroke, Ischemic

Keywords

COVID, stroke, CT, CTA

Brief summary

Multi-centre prospective study evaluating computed tomography angiography studies performed for stroke patients as a diagnostic and prognostic imaging biomarker.

Detailed description

Diagnosis of coronavirus disease 2019 (COVID-19) relies on clinical features and reverse-transcriptase polymerase chain reaction (RT-PCR) testing. The latter is constrained by limited sensitivity and a timescale of hours to yield results, with no point-of-care test widely available. A dedicated computed tomography study of the chest is likely to be more sensitive than RT-PCR for COVID-19. Carotid computed tomography angiography (CTA) is a routine acute stroke investigation and includes the lung apices. We aim to assess the lung apices on CTA for ground glass opacification and compare this with COVID-19 RT-PCR test results and clinical outcome measures.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

All adult patients presenting with clinical features of acute ischaemic stroke undergoing investigation with computed tomography angiography at presentation.

Exclusion criteria

Poor image quality. No radiologist report available. Computed tomography angiography performed in a non-acute setting.

Design outcomes

Primary

Measure	Time frame	Description
Accuracy of the computed tomography angiography biomarker relative to the COVID-19 RT-PCR test	1 month	Defined by sensitivity, specificity, positive and negative predictive values

Secondary

Measure	Time frame	Description
Prognostic value of the computed tomography biomarker	1 month	Defined by its relationship with 30 day mortality and modified rankin scale following treatment

Countries

United Kingdom

Contacts

Primary ContactNathan Chan, FRCR

covidsalesresearch@gmail.com+44(0)7508192126

Backup ContactTom Booth, FRCR

thomas.booth@kcl.ac.uk+44(0)2032993279

Outcome results